TIL Stock Price, Instil Bio, Inc. Quote, Chart

Market Summary

USD10.60+0.20

Market Closed

1.92%

TIL Stock Price

View Fullscreen

TIL RSI Chart

TIL Valuation

Market Cap

68.9M

Price/Earnings (Trailing)

-0.44

Price/Sales (Trailing)

7.78

EV/EBITDA

-0.41

Price/Free Cashflow

-0.67

TIL Price/Sales (Trailing)

TIL Profitability

EBT Margin

-1760.51%

Return on Equity

-69.12%

Return on Assets

-47.93%

Free Cashflow Yield

-148.96%

TIL Fundamentals

TIL Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

22.22%

Rev. Growth (Qtr)

-5.1%

TIL Earnings

Earnings (TTM)

-156.1M

Earnings Growth (Yr)

76%

Earnings Growth (Qtr)

80.83%

Breaking Down TIL Revenue

Last 7 days

-0.4%

Last 30 days

-4.5%

Last 90 days

-11.2%

Trailing 12 Months

1600.4%

How does TIL drawdown profile look like?

TIL Financial Health

Current Ratio

15.22

TIL Investor Care

Buy Backs (1Y)

95.00%

Diluted EPS (TTM)

-24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.6M	7.4M	8.5M	8.9M
2022	169.0K	640.0K	1.9M	3.7M
2021	0	109.0K	89.0K	72.0K
2020	0	0	0	138.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Instil Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2022	mcgaughy r kent jr	sold	-	-	-260,323	-
Mar 23, 2021	mcgaughy r kent jr	acquired	-	-	8,028,790	-
Mar 23, 2021	mcgaughy r kent jr	bought	9,000,000	20.00	450,000	-
Mar 23, 2021	nielsen jack	acquired	-	-	12,186,800	-
Mar 23, 2021	nielsen jack	bought	6,000,000	20.00	300,000	-
Mar 23, 2021	shah nimish p	bought	6,000,000	20.00	300,000	-
Mar 23, 2021	shah nimish p	acquired	-	-	6,565,080	-
Mar 23, 2021	vivo capital ix, llc	acquired	-	-	12,186,800	-
Mar 23, 2021	vivo capital ix, llc	bought	6,000,000	20.00	300,000	-
Mar 23, 2021	curative ventures v llc	bought	9,000,000	20.00	450,000	-

Which funds bought or sold TIL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	216	734	-%
Apr 24, 2024	BML Capital Management, LLC	new	-	3,766,340	3,766,340	2.48%
Apr 22, 2024	Vivo Capital, LLC	reduced	-	1,985,380	6,742,850	0.53%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-1,143,880	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	991,377	991,377	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-13,577	-	-%
Feb 20, 2024	Cable Car Capital LLC	new	-	1,966,700	1,966,700	2.04%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-428,000	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	new	-	1,939,930	1,939,930	0.06%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-17,008	-	-%

Are Funds Buying or Selling TIL?

Are funds buying TIL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TIL

No. of Funds

Unveiling Instil Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 02, 2024	bml investment partners, l.p.	5.3%	346,190	SC 13G
Apr 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 22, 2022	ra capital management, l.p.	5.93%	7,670,793	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Instil Bio, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	8-K	Current Report
Apr 02, 2024	SC 13G	Major Ownership Report
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Feb 14, 2024	8-K	Current Report
Feb 13, 2024	4	Insider Trading

Peers (Alternatives to Instil Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Instil Bio, Inc. News

Latest updates

Instil Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-5.1%	2,195,000	2,313,000	2,287,000	2,071,000	1,796,000	1,276,000	486,000	97,000	35,000	22,000	15,000	-	52,000	42,000	44,000
Operating Expenses	-80.5%	13,020,000	66,716,000	20,987,000	58,446,000	56,799,000	56,649,000	58,724,000	54,286,000	53,752,000	43,024,000	35,381,000	17,477,000	7,763,000	4,635,000	3,907,000
S&GA Expenses	-9.0%	10,872,000	11,941,000	11,518,000	13,222,000	12,910,000	16,989,000	17,224,000	15,112,000	11,175,000	13,960,000	14,195,000	7,230,000	2,855,000	2,398,000	1,900,000
R&D Expenses	-76.6%	1,983,000	8,492,000	8,459,000	20,670,000	20,722,000	39,660,000	41,500,000	39,174,000	42,577,000	29,064,000	21,186,000	10,247,000	4,908,000	2,237,000	2,007,000
EBITDA Margin	25.7%	-16.48	-22.18	-23.85	-38.79	-59.47	-116	-325	-1,093	-2,138	-	-	-	-	-	-
Interest Expenses	-1.1%	1,980,000	2,003,000	590,000	636,000	745,000	807,000	331,000	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-605,000	-371,000	-609,000	-488,000	1,060,000	-658,000	-159,000	151,000	-	-	-
Earnings Before Taxes	80.8%	-12,925,000	-67,432,000	-18,662,000	-57,068,000	-54,449,000	-56,595,000	-59,601,000	-54,605,000	-54,290,000	-43,663,000	-35,470,000	-17,034,000	-7,262,000	-9,202,000	-4,089,000
EBT Margin	24.6%	-17.61	-23.34	-25.14	-40.45	-61.63	-118	-331	-1,112	-2,177	-1,342	-762	-272	-	-	-
Net Income	80.8%	-12,925,000	-67,432,000	-18,662,000	-57,068,000	-53,844,000	-56,224,000	-58,992,000	-54,117,000	-55,350,000	-43,005,000	-35,311,000	-17,185,000	-7,262,000	-9,202,000	-4,089,000
Net Income Margin	24.3%	-17.61	-23.27	-25.01	-40.17	-61.06	-118	-330	-1,111	-2,177	-1,332	-760	-273	-	-	-
Free Cashflow	31.4%	-13,439,000	-19,584,000	-26,540,000	-43,129,000	-49,988,000	-66,076,000	-73,403,000	-75,286,000	-61,254,000	-51,140,000	-40,717,000	-21,125,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-4.3%	326	340	408	427	482	533	569	565	610	647	673	696	319
Current Assets	-17.8%	161	196	221	240	269	314	368	391	464	523	574	614	246
Cash Equivalents	0.7%	9.00	9.00	22.00	27.00	44.00	42.00	43.00	62.00	38.00	21.00	567	610	242
Net PPE	-0.5%	139	139	181	180	197	185	167	141	122	104	79.00	63.00	55.00
Goodwill	-	-	-	-	-	-	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Liabilities	-6.1%	100	106	112	116	119	122	110	56.00	55.00	46.00	37.00	31.00	27.00
Current Liabilities	-21.6%	11.00	13.00	18.00	27.00	33.00	42.00	43.00	37.00	41.00	32.00	24.00	17.00	13.00
Shareholder's Equity	-3.5%	226	234	297	311	364	411	458	509	555	601	635	665	-
Retained Earnings	-2.3%	-580	-568	-500	-481	-424	-371	-314	-255	-201	-146	-103	-68.05	-44.92
Additional Paid-In Capital	0.6%	807	803	798	794	789	782	774	765	757	748	739	733	6.00
Shares Outstanding	-100.0%	-	130	130	130	-	129	129	129	129	129	82.00	35.00	21.00
Float	-	-	-	34.00	-	-	-	286	-	-	-	1,071	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	7.2%	-13,381	-14,426	-19,560	-34,662	-36,976	-40,877	-47,260	-55,051	-42,790	-29,395	-32,224	-17,729	-16,823	-7,235	-3,276	-2,282
Share Based Compensation	-2.5%	4,553	4,670	4,413	4,530	6,643	7,982	8,323	7,493	8,904	8,736	5,745	2,812	415	330	899	62.00
Cashflow From Investing	501.6%	13,950	2,319	10,331	14,528	32,802	25,373	-21,501	77,867	59,958	-516,732	-8,493	-9,129	-45,271	-4,302	-275	-1,274
Cashflow From Financing	100.0%	-	-587	4,202	4,467	6,202	14,722	50,624	338	198	121	-1,860	394,705	133,071	114	179,863	-

TIL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 39,604	$ 141,056
General and administrative	47,553	62,235
Restructuring and impairment charges	72,012	23,167
Total operating expenses	159,169	226,458
Loss from operations	(159,169)	(226,458)
Interest income	8,866	3,655
Interest expense	(5,209)	(1,883)
Other expense, net	(575)	(564)
Loss before income tax benefit	(156,087)	(225,250)
Income tax benefit	0	2,073
Net loss	(156,087)	(223,177)
Other comprehensive income (loss):
Foreign currency translation	(433)	9
Unrealized gain (loss) on available-for-sale securities, net	578	(415)
Net comprehensive loss	$ (155,942)	$ (223,583)
Net loss per share, basic (in dollars per share)	$ (24.00)	$ (34.46)
Net loss per share, diluted (in dollars per share)	$ (24.00)	$ (34.46)
Weighted-average shares used in computing net loss per share, basic (in shares)	6,503,913	6,475,631
Weighted-average shares used in computing net loss per share, diluted (in shares)	6,503,913	6,475,631

TIL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,195	$ 43,716
Restricted cash	1,501	0
Marketable securities	141,161	217,204
Prepaid expenses and other current assets	8,902	8,458
Total current assets	160,759	269,378
Property, plant and equipment, net	138,684	196,880
Operating lease right-of-use assets	2,387	12,457
Long-term investments	23,161	0
Other long-term assets	639	3,413
Total assets	325,630	482,128
Current liabilities:
Accounts payable	1,212	2,359
Accrued expenses and other current liabilities	9,347	30,069
Contingent consideration, current portion	0	360
Total current liabilities	10,559	32,788
Contingent consideration, net of current portion	4,858	7,882
Operating lease liabilities, non-current	2,877	5,171
Loan payable	81,427	72,350
Other long-term liabilities	80	332
Total liabilities	99,801	118,523
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of December 31, 2023, and 2022	0	0
Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,503,913 shares issued and outstanding as of December 31, 2023, and 2022	0	0
Additional paid-in capital	807,158	788,992
Accumulated other comprehensive loss	(348)	(493)
Accumulated deficit	(580,981)	(424,894)
Total stockholders’ equity	225,829	363,605
Total liabilities and stockholders’ equity	$ 325,630	$ 482,128

About Instil Bio, Inc.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

CEO	Mr. Bronson Crouch
WEBSITE	https://instilbio.com
INDUSTRY	Biotechnology
EMPLOYEES	192

Instil Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Instil Bio, Inc.? What does TIL stand for in stocks?

TIL is the stock ticker symbol of Instil Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Instil Bio, Inc. (TIL)?

As of Fri Apr 26 2024, market cap of Instil Bio, Inc. is 68.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TIL stock?

You can check TIL's fair value in chart for subscribers.

What is the fair value of TIL stock?

You can check TIL's fair value in chart for subscribers. The fair value of Instil Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Instil Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Instil Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether TIL is over valued or under valued. Whether Instil Bio, Inc. is cheap or expensive depends on the assumptions which impact Instil Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TIL.

What is Instil Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, TIL's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 7.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TIL PE ratio will change depending on the future growth rate expectations of investors.